Functional Switching of TGF-beta1 Signaling in Liver Cancer Via Epigenetic Modulation of a Single CpG Site in TTP Promoter
Overview
Authors
Affiliations
Background & Aims: Acquisition of resistance to the antiproliferative effect of transforming growth factor (TGF)-beta1 is crucial for the malignant progression of cancers. In this study, we sought to determine whether deregulated expression of tristetrapolin (TTP), a negative posttranscriptional regulator of c-Myc, confers resistance to the antiproliferative effects of TGF-beta1 on liver cancer cells.
Methods: The epigenetics of TTP promoter regulation and its effects on TGF-beta1 signaling were examined in hepatocellular carcinoma (HCC) cell lines and patient tissues.
Results: TTP was down-regulated in HCC cell lines (10/11), compared with normal liver, as well as in tumor tissues (19/24) from paired HCC specimens. Methylation of a specific single CpG site located within the TGF-beta1-responsive region (TRR) of the TTP promoter was significantly associated with TTP down-regulation in both HCC cell lines and tumor tissues (r = -0.606383, P < .001). The singly methylated CpG site was specifically bound by a transcriptional repressor complex consisting of MECP2/c-Ski/DNMT3A and abolished the TGF-beta1-induced as well as basal-level expression of TTP. The epigenetic inactivation of TTP led to an increased half-life of c-Myc mRNA and blocked the cytostatic effect of TGF-beta1. Statistically significant correlations were observed between the single CpG site methylation and expression levels of TTP or c-Myc in clinical samples of HCC.
Conclusions: Abrogation of the post-transcriptional regulation of c-Myc via methylation of a specific single CpG site in the TTP promoter presents a novel mechanism for the gain of selective resistance to the antiproliferative signaling of TGF-beta1 in HCC.
Gellee N, Legrand N, Jouve M, Devaux P, Dubuquoy L, Sobolewski C Cancers (Basel). 2025; 17(3).
PMID: 39941720 PMC: 11815756. DOI: 10.3390/cancers17030348.
Yan W, Rao D, Fan F, Liang H, Zhang Z, Dong H Front Oncol. 2024; 14:1407434.
PMID: 38962270 PMC: 11220127. DOI: 10.3389/fonc.2024.1407434.
Nejati-Koshki K, Roberts C, Babaei G, Rastegar M Cancers (Basel). 2023; 15(10).
PMID: 37345019 PMC: 10216337. DOI: 10.3390/cancers15102683.
Chen Z, Fan N, Shen G, Yang J Inflammation. 2022; 46(2):700-717.
PMID: 36422840 DOI: 10.1007/s10753-022-01766-2.
Sobolewski C, Dubuquoy L, Legrand N Cancers (Basel). 2022; 14(14).
PMID: 35884580 PMC: 9319505. DOI: 10.3390/cancers14143516.